Cargando…
Recent Updates on Type 1 Diabetes Mellitus Management for Clinicians
Type 1 diabetes mellitus (T1DM) is a chronic autoimmune condition that requires life-long administration of insulin. Optimal management of T1DM entails a good knowledge and understanding of this condition both by the physician and the patient. Recent introduction of novel insulin preparations, techn...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Korean Diabetes Association
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5842299/ https://www.ncbi.nlm.nih.gov/pubmed/29504302 http://dx.doi.org/10.4093/dmj.2018.42.1.3 |
_version_ | 1783304872614952960 |
---|---|
author | Iqbal, Ahmed Novodvorsky, Peter Heller, Simon R. |
author_facet | Iqbal, Ahmed Novodvorsky, Peter Heller, Simon R. |
author_sort | Iqbal, Ahmed |
collection | PubMed |
description | Type 1 diabetes mellitus (T1DM) is a chronic autoimmune condition that requires life-long administration of insulin. Optimal management of T1DM entails a good knowledge and understanding of this condition both by the physician and the patient. Recent introduction of novel insulin preparations, technological advances in insulin delivery and glucose monitoring, such as continuous subcutaneous insulin infusion (CSII) and continuous glucose monitoring and improved understanding of the detrimental effects of hypoglycaemia and hyperglycaemia offer new opportunities and perspectives in T1DM management. Evidence from clinical trials suggests an important role of structured patient education. Our efforts should be aimed at improved metabolic control with concomitant reduction of hypoglycaemia. Despite recent advances, these goals are not easy to achieve and can put significant pressure on people with T1DM. The approach of physicians should therefore be maximally supportive. In this review, we provide an overview of the recent advances in T1DM management focusing on novel insulin preparations, ways of insulin administration and glucose monitoring and the role of metformin or sodium-glucose co-transporter 2 inhibitors in T1DM management. We then discuss our current understanding of the effects of hypoglycaemia on human body and strategies aimed at mitigating the risks associated with hypoglycaemia. |
format | Online Article Text |
id | pubmed-5842299 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Korean Diabetes Association |
record_format | MEDLINE/PubMed |
spelling | pubmed-58422992018-03-13 Recent Updates on Type 1 Diabetes Mellitus Management for Clinicians Iqbal, Ahmed Novodvorsky, Peter Heller, Simon R. Diabetes Metab J Review Type 1 diabetes mellitus (T1DM) is a chronic autoimmune condition that requires life-long administration of insulin. Optimal management of T1DM entails a good knowledge and understanding of this condition both by the physician and the patient. Recent introduction of novel insulin preparations, technological advances in insulin delivery and glucose monitoring, such as continuous subcutaneous insulin infusion (CSII) and continuous glucose monitoring and improved understanding of the detrimental effects of hypoglycaemia and hyperglycaemia offer new opportunities and perspectives in T1DM management. Evidence from clinical trials suggests an important role of structured patient education. Our efforts should be aimed at improved metabolic control with concomitant reduction of hypoglycaemia. Despite recent advances, these goals are not easy to achieve and can put significant pressure on people with T1DM. The approach of physicians should therefore be maximally supportive. In this review, we provide an overview of the recent advances in T1DM management focusing on novel insulin preparations, ways of insulin administration and glucose monitoring and the role of metformin or sodium-glucose co-transporter 2 inhibitors in T1DM management. We then discuss our current understanding of the effects of hypoglycaemia on human body and strategies aimed at mitigating the risks associated with hypoglycaemia. Korean Diabetes Association 2018-02 2018-02-23 /pmc/articles/PMC5842299/ /pubmed/29504302 http://dx.doi.org/10.4093/dmj.2018.42.1.3 Text en Copyright © 2018 Korean Diabetes Association http://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Review Iqbal, Ahmed Novodvorsky, Peter Heller, Simon R. Recent Updates on Type 1 Diabetes Mellitus Management for Clinicians |
title | Recent Updates on Type 1 Diabetes Mellitus Management for Clinicians |
title_full | Recent Updates on Type 1 Diabetes Mellitus Management for Clinicians |
title_fullStr | Recent Updates on Type 1 Diabetes Mellitus Management for Clinicians |
title_full_unstemmed | Recent Updates on Type 1 Diabetes Mellitus Management for Clinicians |
title_short | Recent Updates on Type 1 Diabetes Mellitus Management for Clinicians |
title_sort | recent updates on type 1 diabetes mellitus management for clinicians |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5842299/ https://www.ncbi.nlm.nih.gov/pubmed/29504302 http://dx.doi.org/10.4093/dmj.2018.42.1.3 |
work_keys_str_mv | AT iqbalahmed recentupdatesontype1diabetesmellitusmanagementforclinicians AT novodvorskypeter recentupdatesontype1diabetesmellitusmanagementforclinicians AT hellersimonr recentupdatesontype1diabetesmellitusmanagementforclinicians |